MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41523-026-00950-z

Медицинская библиотека · NPJ breast cancer · 2026

Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial.

O'Shaughnessy Joyce, Bidard Francois-Clement, Neven Patrick, Casalnuovo Monica Lis, Aftimos Philippe, Saura Cristina, Harbeck Nadia, Carey Lisa A, Curigliano Giuseppe, Garcia-Saenz Jose A, Abad Maria Fernandez, Paula Larissa de, Park Yeon Hee, Ozyilkan Ozgur, Munoz Maria, Barrett Emily, Cao Shanshan, Chawla Aarti, Jhaveri Komal L

СтатьяПеревод в очереди

Аннотация

In EMBER-3 (NCT04975308), among patients with ER + , HER2- advanced breast cancer (ABC) with recurrence/progression on/after endocrine therapy (ET), imlunestrant significantly prolonged PFS versus standard ET in patients with ESR1 mutations, and imlunestrant + abemaciclib prolonged PFS versus imlunestrant in the overall population. We report the incidence, severity, timing, and management of common treatment-emergent adverse events (TEAEs), including safety profiles of select subgroups. In both imlunestrant-containing arms, the most common TEAEs were reversible, low grade, single occurrences; occurred early in treatment; and resulted in few treatment discontinuations (imlunestrant, 5%; imlunestrant + abemaciclib, 6%). TEAEs in imlunestrant+abemaciclib arm were managed with dose adjustments (61%) and supportive medication. Imlunestrant monotherapy had a similar safety profile between patients aged <65 and ≥65 years, while imlunestrant + abemaciclib had a similar safety profile to other abemaciclib+ET combinations in both age groups. Imlunestrant and imlunestrant + abemaciclib provide effective, convenient oral therapy with a favorable and manageable safety profile for patients with ER+, HER2- ABC with recurrence/progression on/after ET.

Для цитирования: O'Shaughnessy Joyce, Bidard Francois-Clement, Neven Patrick, Casalnuovo Monica Lis, Aftimos Philippe, Saura Cristina, Harbeck Nadia, Carey Lisa A, Curigliano Giuseppe, Garcia-Saenz Jose A, Abad Maria Fernandez, Paula Larissa de, Park Yeon Hee, Ozyilkan Ozgur, Munoz Maria, Barrett Emily, Cao Shanshan, Chawla Aarti, Jhaveri Komal L. Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial.. NPJ breast cancer. 2026. DOI: 10.1038/s41523-026-00950-z.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.